Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
【発明の名称】アジュバントおよび免疫刺激活性を有するトリテルペンサポニンアナログ
Document Type and Number:
Japanese Patent JP2002504099
Kind Code:
A
Abstract:
The present invention is directed to novel chemical compounds in which a lipophilic moiety such as a lipid, fatty acid, polyethylene glycol or terpene is covalently attached to a non-acylated or desacylated triterpene saponin via a carboxyl group present on the 3-O-glucuronic acid of the triterpene saponin. The attachment of a lipophile moiety to the 3-O-glucuronic acid of a saponin such as Quillaja desacylsaponin, lucyoside P, or saponin from Gypsophila, Saponaria and Acanthophyllum enhances their adjuvant effects on humoral and cell mediated immunity. Additionally, the attachment of a lipophile moiety to the 3-O-glucuronic acid residue of non- or des-acylsaponin yields a saponin analog that is easier to purify, less toxic, chemically more stable, and possesses equal or better adjuvant properties than the original saponin.

Inventors:
Marsani, Dante Jay.
Application Number:
JP55055598A
Publication Date:
February 05, 2002
Filing Date:
May 20, 1998
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
Galenica Pharmaceuticals, Inc.
International Classes:
A61K31/704; A61K36/00; A61K39/39; A61K47/48; A61P37/04; A61P43/00; C07H15/256; A61K31/56; C07J63/00; (IPC1-7): C07J63/00; A61K31/56; A61K31/704; A61K35/78; A61P37/04; A61P43/00
Domestic Patent References:
JPH07509440A1995-10-19
JPH07504156A1995-05-11
JPH04501714A1992-03-26
Other References:
JPN6009013310, SOLTYSIK, S. et al., "Structure/function studies of QS−21 adjuvant: assessment of triterpene aldehyde and glucuronic acid", Vaccine, 1995, Volume 13, Issue 15, Pages 1403−1410
JPN6009013311, BOMFORD, R. et al., "Adjuvanticity and ISCOM formation by structurally diverse saponins", Vaccine, 1992, Volume 10, Issue 9,, Pages 572−577
JPN6009013312, SAITO, S. et al., "Synthetic studies on the relationship between anti−HIV activities and micelle forming abilities of v", European Journal of Medicinal Chemistry, 1996, Volume 31, Issue 5, Pages 365−381
Attorney, Agent or Firm:
Shusaku Yamamoto